{
    "Trade/Device Name(s)": [
        "MEG-2B Blood Glucose Monitoring System",
        "MEG-2B Pro Blood Glucose Monitoring System",
        "MEG-2B Blood Glucose Test Strips",
        "MEG-2B Pro Blood Glucose Test Strips",
        "MEG-2B Glucose Control Solutions"
    ],
    "Submitter Information": "Apex Biotechnology Corp.",
    "510(k) Number": "K120448",
    "Predicate Device Reference 510(k) Number(s)": [
        "K101204"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "NBW",
        "JJX"
    ],
    "Summary Letter Date": "March 16, 2012",
    "Summary Letter Received Date": "March 20, 2012",
    "Submission Date": "February 6, 2012",
    "Regulation Number(s)": [
        "21CFR862.1345",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Glucose Test System",
        "Single (specified) analyte controls (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MEG-2B Blood Glucose Meter",
        "MEG-2B Pro Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Monitoring System",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Apex Biotechnology MEG-2B and MEG-2B Pro blood glucose monitoring systems and control solutions for quantitative measurement of glucose in whole blood.",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood for self-testing by diabetics (MEG-2B), and for multiple patient use in clinical settings by professionals (MEG-2B Pro); not for diabetes diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}